RepliCel Life Sciences Inc REPCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.04–0.04
- 52-Week Range
- $0.03–0.19
- Bid/Ask
- $0.02 / $0.10
- Market Cap
- $2.78 Mil
- Volume/Avg
- 550 / 9,450
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.replicel.com
Valuation
|
Metric
|
REPCF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 7.56 |
Price/Cash Flow | — |
Price/Earnings
REPCF
Financial Strength
|
Metric
|
REPCF
|
|---|---|
Quick Ratio | 0.09 |
Current Ratio | 0.13 |
Interest Coverage | −37.83 |
Quick Ratio
REPCF
Profitability
|
Metric
|
REPCF
|
|---|---|
Return on Assets (Normalized) | 81.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
REPCF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Plvxhtwzjr | Yyqrv | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pfsqltlx | Blgmx | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jbzqkgmh | Sdgcwzh | $98.8 Bil | |
MRNA
| Moderna Inc | Gdmcgmzmk | Lyv | $38.8 Bil | |
ARGX
| argenx SE ADR | Fqhxwqnsr | Ywnh | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Bbnzpscf | Qvt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pqtdzynj | Cckrn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Grcnrslg | Knvpz | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nhbclcqqh | Nbcqmdb | $12.4 Bil | |
INCY
| Incyte Corp | Ncpqlzyd | Zfyyt | $11.9 Bil |